Page Title
Clinical Trial Finder
Ask About Participating in This Study
Anti-InfectiveEnrolling
Study to evaluate inhaled RSP-1502 in adults with cystic fibrosis and Pseudomonas aeruginosa, protocol number Respirion RESPIR-102The following information will be used to determine eligibility for this study. Fill out the form and click “Preview Message.” This will draft an email you can send directly to the Research Coordinator. Please note, this does not guarantee entry into this particular study.
* indicates required field
Personal Information
Add more details about who you are and how you would like to be contacted (e.g. phone, text, email).
(this will open in your email program)
Anti-InfectiveEnrolling
Study to evaluate inhaled RSP-1502 in adults with cystic fibrosis and Pseudomonas aeruginosa, protocol number Respirion RESPIR-102
This study will look at the safety of inhaled RSP-1502, a drug intended to treat infections in the lung. RSP-1502, which includes the antibiotic tobramycin, will be compared to tobramycin alone. The study will measure the drug's safety, how well it works, and how the body processes it. Four doses of RSP-1502 will be tested to find the best dose.
-
Age:
18 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
5
-
Length of Participation:
28 days
Related Topics
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Check the Drug Development Pipeline
We’re attacking CF from every angle. Learn about the status of CF drugs in development.
Learn More